Redeye sees an attractive long-term growth case that continues to deliver short-term increases in sales and gross margins. The order book is strong, and with the CMS decision, the outlook into 2022 remains strong. We adjust our short term estimates due to higher cost incurred to drive growth into 2022, while the slightly higher conviction on development in the medium term makes us increase our fair value range to SEK 48 to 135 (45 -130) with a new base Case of SEK 95 (90) per share.